Overexpression in melanomas at different stages, restricted tissue distribution in normal tissues and a central role in cancer cell motility, metastasis and tissue invasion, render CSPG4 an attractive therapeutic target for applications, including monoclonal antibodies that may be used in adjuvant and in advanced disease settings. This evidence concerns the gene CSPG4 and melanoma.